Sign in to view content

Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials

Dilsher S. Dhoot, MD

Video
Published 2021

Related

Anti-VEGF Resistant Subretinal Fluid Associated With Reduced Risk of Macular Atrophy and Better Vision: Drug-Induced Choroidal New Vessel Homeostasis?
Marco A. Zarbin, MD, PhD
Annual Meeting Talks
2020
Extended Q16W Dosing Potential for Faricimab in Neovascular Age-Related Macular Degeneration (nAMD): STAIRWAY Phase 2 Trial
Philip J. Ferrone, MD, FASRS
Annual Meeting Talks
2019
National vs International Outcomes and Practice Patterns of Intravitreal Anti-VEGF Injections for Retinopathy of Prematurity
Nimesh A. Patel, MD
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more